Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Image-guided Photodynamic Therapy (PDT) Treatment of Pre-malignant and Malignant Oral Lesions
NCT06876038Phase 2Not yet recruiting
- Sponsor
- University of Massachusetts Boston
- Start
- Sep 2026
- Primary completion
- May 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of 5-aminolevulinic acid in oral cancer, oral leukoplakia, oral lichen planus (OLP) and 1 more, sponsored by University of Massachusetts Boston. Primary endpoint: Efficacy of 5-ALA based PDT to treat HGD-OPML. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
5-aminolevulinic acid
03
Conditions
oral canceroral leukoplakiaoral lichen planus (OLP)oral squamous cell carcinoma (OSCC)
Beyond the preview
Go deeper on NCT06876038.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06876038.